BR Shetty's $5.4bn NMC Health fraud trial opens — largest private healthcare fraud case in UAE corporate history

BR Shetty, founder of NMC Health, faces trial this week over an alleged $5.4 billion fraud that collapsed the UAE's largest private hospital network and left creditors counting losses six years on.

The case is the largest corporate fraud trial connected to a UAE-headquartered healthcare business. NMC, once valued at over $8 billion on the London Stock Exchange, operated more than 200 facilities across Abu Dhabi and Dubai before entering administration in April 2020. The fraud centred on billions in debt concealed from auditors, investors, and the company's own board.

What prosecutors allege

Prosecutors contend that Shetty and associates falsified financial statements, inflated asset values, and arranged undisclosed borrowing through related-party transactions. Four alleged failures are at the centre of the case:

• Financial statements systematically falsified across the group over multiple years
• Asset values inflated to support ongoing undisclosed borrowing
• Related-party transactions used to hide liabilities from auditors, investors, and the company's own board
• Total undisclosed debt at collapse exceeding $6.6 billion against reported figures roughly half that size

Banks including Abu Dhabi Commercial Bank, Dubai Islamic Bank, and Standard Chartered were among the largest creditors holding facilities they did not know existed. Administrators from Alvarez & Marsal, appointed in 2020, spent two years reconstructing NMC's actual balance sheet. Their findings form the evidentiary backbone of the current prosecution.

How the collapse unfolded

The unravelling began in December 2019 when short-seller Muddy Waters Research published a report questioning NMC's asset valuations and cash balances. The company initially pushed back. Within four months it was in administration. The collapse (from FTSE 100 constituent to insolvent in under 120 days) ranks among the fastest large-cap failures in London market history.

The Abu Dhabi Department of Health and UAE healthcare licensing bodies were not direct parties to the securities fraud, but the episode prompted a governance review across DOH-regulated facilities on financial transparency requirements for multi-site private operators. MOHAP subsequently tightened beneficial ownership disclosure rules for healthcare group licensing applications.

What operators should watch

For CFOs at large private healthcare groups, the trial will produce detailed testimony about how concealed related-party debt was structured and why standard audit procedures failed to detect it. That evidence has practical value: it documents the specific control gaps that allowed $6.6 billion in liabilities to go undetected across a heavily regulated sector.

The case carries direct implications for healthcare M&A due diligence in the region. Several of NMC's former facilities were acquired by Pure Health and other Abu Dhabi-based operators at distressed valuations after 2020. Future acquirers of privatised or distressed healthcare infrastructure will face harder questions about historical liability exposure.

A verdict is unlikely before late 2027 if the trial proceeds without significant delays. Creditor recovery proceedings run in parallel through the UK courts, with banks seeking proportional recovery from remaining NMC assets still under administration.